90670

Pneumococcal Conjugate Vaccine, 13-Valent (PCV13), Intramuscular Use

The 13-valent pneumococcal conjugate vaccine (PCV13), represented by CPT code 90670, is a sterile suspension of saccharides containing the capsular antigens of 13 specific serotypes of Streptococcus pneumoniae: 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F. Each of these polysaccharides is individually conjugated to a non-toxic variant of the diphtheria toxin known as CRM197. This conjugation is a critical biochemical process because it converts the immune response from a T-cell independent pathway, which is typical of pure polysaccharide vaccines, to a T-cell dependent pathway. This change allows for the induction of immunologic memory and is particularly effective in stimulating a robust immune response in infants and young children, whose immune systems do not reliably respond to unconjugated polysaccharides. PCV13 is primarily indicated for the prevention of invasive pneumococcal disease, including bacteremia, sepsis, and meningitis, as well as non-invasive diseases such as pneumonia and acute otitis media caused by the included serotypes. The vaccine is administered via intramuscular injection, most commonly in the anterolateral aspect of the thigh for infants or the deltoid muscle for older children and adults. Clinically, it has been a fundamental component of pediatric immunization schedules since its introduction, replacing the earlier 7-valent formulation. In adults, it was historically recommended for those aged 65 and older and individuals with specific immunocompromising conditions, although current clinical guidelines from the Advisory Committee on Immunization Practices (ACIP) often now prioritize newer formulations such as PCV15 or PCV20 for certain populations. When billing for 90670, providers must document the vaccine's brand name, manufacturer, lot number, and the specific site of administration to ensure accurate clinical tracking and reimbursement.

Clinical Indications

  • Routine active immunization for the prevention of invasive disease caused by S. pneumoniae in infants and children
  • Prevention of acute otitis media in children caused by vaccine-specific serotypes
  • Immunization for adults aged 65 years and older (subject to shared clinical decision-making or specific risk factors)
  • Immunization for individuals aged 6 through 64 with high-risk conditions such as functional or anatomic asplenia
  • Prevention of pneumococcal pneumonia in immunocompromised patients including those with HIV, leukemia, or chronic renal failure
  • Immunization for patients with cochlear implants or cerebrospinal fluid (CSF) leaks

Procedure Steps

  1. Verify patient identity and perform a pre-vaccination screening for allergies (e.g., to diphtheria toxoid) or acute illness
  2. Review the patient's immunization history to ensure the appropriate interval since previous pneumococcal doses
  3. Provide the patient or guardian with the most current Vaccine Information Statement (VIS) and answer any questions
  4. Perform hand hygiene and prepare the vaccine syringe by shaking the prefilled syringe or vial to obtain a homogenous white suspension
  5. Clean the injection site (typically the deltoid for adults or anterolateral thigh for infants) with an alcohol swab
  6. Administer 0.5 mL of the vaccine via intramuscular injection at a 90-degree angle
  7. Withdraw the needle and apply gentle pressure; do not massage the site
  8. Dispose of sharps in a biohazard container and document the lot number, manufacturer, and administration site in the EHR
  9. Observe the patient for 15 minutes post-injection for signs of immediate allergic reactions or syncope

Coding Guidelines

  • CPT 90670 represents the vaccine product only; a separate administration code must be reported
  • For pediatric administration with physician counseling, use 90460 for the first component and 90461 if applicable (though PCV13 is typically one component)
  • For administration without counseling or for adults, use 90471 (first injection) or 90472 (subsequent injections)
  • Medicare claims for the administration should use HCPCS code G0009 rather than the CPT administration codes
  • If the vaccine is administered during a preventive medicine visit, the office visit code and 90670 are both reported
  • If an E/M service is performed for a significant, separately identifiable reason on the same day, append modifier 25 to the E/M code
  • Check current ACIP guidelines as 90670 may be superseded by 90671 (PCV15) or 90677 (PCV20) depending on the patient's age and health status

Associated ICD-10 Codes